Marpai, Inc. (MRAI): Entry into a Material Definitive Agreement
Marpai, Inc. (MRAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Marpai Announces $12 Million Private Placement led by Mitchell Companies Tampa, Florida — July 29, 2026 — Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a leader in innovative healthcare technology, Third-Party Administration (“TPA”), and Pharmacy Benefit Ma
How this was made
The 30-second read
Why it matters
This is a primary-source disclosure of a new equity raise framework, with stated minimum and maximum Preferred Stock proceeds ($2M to $5M). The market will focus on dilution mechanics and whether the deal closes on schedule.
Market read
A defined-range Series A Preferred Stock financing is disclosed, which can drive near-term repricing around dilution and capital runway expectations once full terms are reviewed.
What to watch
Traders will need the missing exhibits details (conversion price, discount, liquidation preference, investor rights, and closing conditions) to judge dilution and downside protection.
Background
The 8-K reports Item 1.01 entry into a material definitive agreement and Item 3.02 unregistered sales of equity securities, referencing a Series A Securities Purchase Agreement dated July 29, 2026.
Ticker impact
Marpai, Inc. filed an 8-K disclosing entry into a Series A securities purchase agreement, including a $2M to $5M Preferred Stock sale range.
Near-term bias depends on pricing terms and investor participation, but dilution risk typically pressures the stock until details are digested.
The excerpt confirms a material definitive agreement and an unregistered sale of equity securities, but it does not include the purchase price, conversion terms, or closing outcome, limiting precision on magnitude and direction.
Market effects
Adds another small-cap financing datapoint, but no sector-wide regulatory or competitive signal is disclosed in the excerpt.
No regional macro or cross-border impact is described.
No global market linkage is stated beyond standard securities-law language.
Counterpoint
If the Series A terms are favorable (e.g., limited dilution, strong investor quality, or non-dilutive structure), the financing could reduce liquidity risk and support the stock.
Key entities
- issuerMarpai, Inc.
Delaware corporation filing the 8-K and entering the Series A securities purchase agreement.
- investorMitchell Family Trust II
Identified as the Lead Investor in the agreement.
